Skip to content

Vitamin D for Preventing Recurrent Preeclampsia in Pregnant Women

Role of Vitamin D in Prevention of Preeclampsia Recurrence in Pregnant Women With Previous History of Preeclampsia: A Randomized Controlled Trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07288801
Enrollment
146
Registered
2025-12-17
Start date
2025-08-09
Completion date
2026-02-08
Last updated
2025-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-eclampsia, Pregnancy, Vitamin D

Keywords

pre-eclampsia, pregnancy, recurrence, Vitamin D

Brief summary

The goal of this clinical trial is to find out whether giving vitamin D to pregnant women who had pre-eclampsia in a previous pregnancy helps prevent the condition from coming back. The main question it aims to answer is: Does vitamin D supplementation reduce the chance of pre-eclampsia recurring in pregnant women with a history of pre-eclampsia? To answer this question, pregnant women attending the antenatal clinic at the Department of Obstetrics and Gynaecology, Nishtar Hospital Multan will be invited to join the study. Participants will be randomly assigned to two equal groups: * Vitamin D group: will take 4,000 IU of oral vitamin D until 36 weeks of gestation. * Placebo group: will receive a pill identical in appearance, taste, and consistency but without vitamin D. While on the study medication, each woman will visit the clinic every two weeks. At each visit, her blood pressure will be measured, and if it is 140/90 mmHg or higher, a urine test will check for protein to identify pre-eclampsia as per hospital protocol. Any diagnosis of pre-eclampsia will lead to standard care, and the outcome will be recorded. At the end, researchers will compare how many women in each group developed recurrent pre-eclampsia. This study will help answer whether vitamin D supplementation can safely reduce the risk of pre-eclampsia returning in women with a prior history - a question important for improving pregnancy outcomes and maternal health.

Interventions

DRUGVitamin D

4000 IU of vitamin D will be given orally, once daily till 36-weeks of gestation

Look, smell and taste alike oil emulsion drops, same number, till 36-weeks of gestation

Sponsors

Nishtar Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Gestational age ≥ 20-weeks (on LMP method) ' - Past medical history of pre-eclampsia

Exclusion criteria

* Pre-existing hypertension, cardiac diseases, renal disease, thyrotoxicosis (on history and medical record) * Women presenting with intra-uterine death of the fetus.

Design outcomes

Primary

MeasureTime frameDescription
Pre-eclampsiaFrom enrollment till 36 completed weeks of gestationPregnant women, ≥ 20-weeks of gestation (on LMP method) having blood pressure of ≥140/90 mm of Hg plus protein (+1 or higher) in spot urine examination by dipstick method

Countries

Pakistan

Contacts

Primary ContactTehseen A Principal Investigator, MBBS
tehseenaslam451@gmail.com+92 303 7832417

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026